IL315020A - Antibodies capable of binding to the spike protein of the SARS-COV-2 coronavirus - Google Patents

Antibodies capable of binding to the spike protein of the SARS-COV-2 coronavirus

Info

Publication number
IL315020A
IL315020A IL315020A IL31502024A IL315020A IL 315020 A IL315020 A IL 315020A IL 315020 A IL315020 A IL 315020A IL 31502024 A IL31502024 A IL 31502024A IL 315020 A IL315020 A IL 315020A
Authority
IL
Israel
Prior art keywords
cov
binding
antibodies capable
spike protein
coronavirus sars
Prior art date
Application number
IL315020A
Other languages
English (en)
Hebrew (he)
Inventor
Juthanthip Mongkolsapaya
Gavin Screaton
Original Assignee
Rq Biotechnology Ltd
Juthanthip Mongkolsapaya
Gavin Screaton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2202232.1A external-priority patent/GB202202232D0/en
Priority claimed from GBGB2203423.5A external-priority patent/GB202203423D0/en
Priority claimed from GBGB2212470.5A external-priority patent/GB202212470D0/en
Priority claimed from GBGB2214036.2A external-priority patent/GB202214036D0/en
Priority claimed from GBGB2215418.1A external-priority patent/GB202215418D0/en
Priority claimed from GBGB2301959.9A external-priority patent/GB202301959D0/en
Application filed by Rq Biotechnology Ltd, Juthanthip Mongkolsapaya, Gavin Screaton filed Critical Rq Biotechnology Ltd
Priority claimed from PCT/EP2023/054109 external-priority patent/WO2023156636A1/en
Publication of IL315020A publication Critical patent/IL315020A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL315020A 2022-02-18 2023-02-17 Antibodies capable of binding to the spike protein of the SARS-COV-2 coronavirus IL315020A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB2202232.1A GB202202232D0 (en) 2022-02-18 2022-02-18 Antibodies
GBGB2203423.5A GB202203423D0 (en) 2022-03-11 2022-03-11 Antibodies
GB202206777 2022-05-09
GBGB2212470.5A GB202212470D0 (en) 2022-08-26 2022-08-26 Antibodies
GBGB2214036.2A GB202214036D0 (en) 2022-09-26 2022-09-26 Antibodies
GBGB2215418.1A GB202215418D0 (en) 2022-10-18 2022-10-18 Antibodies
GBGB2301959.9A GB202301959D0 (en) 2023-02-10 2023-02-10 Antibodies
PCT/EP2023/054109 WO2023156636A1 (en) 2022-02-18 2023-02-17 Antibodies capable of binding to the spike protein of coronavirus sars-cov-2

Publications (1)

Publication Number Publication Date
IL315020A true IL315020A (en) 2024-10-01

Family

ID=86497315

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315020A IL315020A (en) 2022-02-18 2023-02-17 Antibodies capable of binding to the spike protein of the SARS-COV-2 coronavirus

Country Status (12)

Country Link
US (1) US20250154231A1 (https=)
EP (1) EP4479425A1 (https=)
JP (1) JP2025507595A (https=)
KR (1) KR20240142594A (https=)
CN (1) CN119403828B (https=)
AU (1) AU2023220851A1 (https=)
CA (1) CA3252608A1 (https=)
CO (1) CO2024012622A2 (https=)
CR (1) CR20240389A (https=)
GB (1) GB2614651B (https=)
IL (1) IL315020A (https=)
MX (1) MX2024010178A (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250289871A1 (en) 2022-04-29 2025-09-18 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
GB202316016D0 (en) * 2023-10-19 2023-12-06 Univ Oxford Innovation Ltd Antibodies
CN121471347B (zh) * 2026-01-12 2026-03-27 中国人民解放军军事科学院军事医学研究院 一种抗SARS-CoV和SARS-CoV-2的全人源单克隆抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250107297A (ko) * 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
MX2021015024A (es) * 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
WO2021229561A1 (en) * 2020-05-14 2021-11-18 The Israel Institute of Biological Research (IIBR) Anti-sars-cov-2 antibodies

Also Published As

Publication number Publication date
KR20240142594A (ko) 2024-09-30
CO2024012622A2 (es) 2024-12-30
MX2024010178A (es) 2024-12-06
GB2614651A (en) 2023-07-12
CR20240389A (es) 2025-05-05
CA3252608A1 (en) 2023-08-24
GB2614651B (en) 2024-03-06
US20250154231A1 (en) 2025-05-15
AU2023220851A1 (en) 2024-09-26
EP4479425A1 (en) 2024-12-25
JP2025507595A (ja) 2025-03-21
GB202305426D0 (en) 2023-05-31
CN119403828A (zh) 2025-02-07
CN119403828B (zh) 2025-12-26

Similar Documents

Publication Publication Date Title
SI4230650T1 (sl) Protitelesa, ki so se sposobna vezati na koničasti protein koronavirusa SARS-COV-2
IL315020A (en) Antibodies capable of binding to the spike protein of the SARS-COV-2 coronavirus
ZA202212246B (en) Compounds specific to coronavirus s protein and uses thereof
CA3248329A1 (en) Antibodies binding to gprc5d
MX2021003393A (es) Proteinas de fijacion a sirp alfa y metodos de uso de estas.
EP3856771A4 (en) Dll3 binding proteins and methods of use
IL287763A (en) Modified coronavirus spike protein s1 subunit
CL2010001427A1 (es) Proteina de union que comprende una cadena polipeptidica capaz de unir un par de antigenos; acido nucleico aislado que codifica dicha proteina de union; vector y celula huesped; metodo para producir proteina de union; composicion farmaceutica que comprende dicha proteina.
EP4232470A4 (en) ANTIBODIES AGAINST CORONAVIRUS SARS-COV-2
MX2021001085A (es) Formulaciones y composiciones farmaceuticas que comprenden una proteina de union a antigeno enmascarada.
WO2009137758A3 (en) Igf-ii/gf-iie binding proteins
IL316176A (en) SIGLEC-8 binding proteins and their uses
EP4477665A4 (en) STEFIN A PROTEIN VARIANTS THAT SPECIFICALLY BIND TO CD40L AND THEIR USES
HK40114408A (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
EP4029882A4 (en) ANTIBODIES SPECIFIC TO BINDING WRS PROTEIN AND USE THEREOF
CA3261708A1 (en) ANTIBODIES BINDING TO CLEC12A
EP4493215A4 (en) ANTIBODIES SPECIFICALLY BINDING TO CD147 AND THEIR USES
GB202209358D0 (en) Protein binding assays
HK40089735A (en) Single domain antibodies binding to sars-cov-2 spike protein
HK40074168A (en) Antibodies that bind to lrp5 proteins and methods of use
EP4519286A4 (en) Modified coronavirus s protein
HK40127592A (en) Antibodies binding to clec12a
CA3273219A1 (en) Antibody binding specifically to asm protein
CA3291671A1 (en) Antibodies capable of binding to ox40, variants thereof and uses thereof
CA3286192A1 (en) Methods of use of multi-specific binding proteins